- Report
- September 2023
- 119 Pages
Global
From €2274EUR$2,500USD£1,948GBP
- Report
- August 2023
- 279 Pages
Global
From €2274EUR$2,500USD£1,948GBP
- Report
- April 2023
- 90 Pages
Global
From €2274EUR$2,500USD£1,948GBP
- Clinical Trials
- December 2021
- 98 Pages
Global
From €2274EUR$2,500USD£1,948GBP
- Clinical Trials
- December 2021
- 93 Pages
Global
From €2274EUR$2,500USD£1,948GBP
- Report
- May 2026
- 150 Pages
Australia
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Brazil
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Canada
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Germany
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
India
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Indonesia
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Italy
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Japan
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Malaysia
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Mexico
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Netherlands
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
China
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
Saudi Arabia
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
South Africa
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 150 Pages
South Korea
From €4411EUR$4,850USD£3,779GBP

The Metabolic Disorder Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It includes drugs used to treat metabolic disorders such as diabetes, obesity, and hyperlipidemia. These drugs are used to regulate the body's metabolism, which is the process of converting food into energy. Common drugs used to treat metabolic disorders include insulin, sulfonylureas, biguanides, thiazolidinediones, and GLP-1 agonists. These drugs are used to control blood sugar levels, reduce cholesterol, and promote weight loss.
The Metabolic Disorder Drug market is highly competitive, with many companies offering a variety of drugs to treat metabolic disorders. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Other companies in the market include Boehringer Ingelheim, Takeda, and Pfizer. Show Less Read more